SAN FRANCISCO — If last year was a chance for Chinese companies to bet big on biotech and pharma — and also to contend with some disappointment and scandal — this year already appears to be a chance for them to flood the zone.

Chinese companies had a noticeably more visible presence at this week’s J.P. Morgan Healthcare Conference, the industry’s biggest business gathering of the year. U.S. executives and investors have been soaking up the pitch for Chinese biopharma and showing enthusiasm.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This was a very disappointing fluffy article with only one fact, that one of the many conferences has more attendance. Everyone I know is astounded by the decline in the number of Chinese attendees and with what feels like a decline overall in attendance at Biotech Showcase and JP Morgan. That is an important story because it is a weathervane for things to come. Maybe I and a twenty other people are wrong in our view that this is a very different attendance profile. That is why we need Stat to really analyze this.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy